BOCA RATON, FL -- (Marketwire) -- 03/23/09 -- Vicor Technologies, Inc. (OTCBB: VCRT) today announced that it has retained the services of Cameron Associates, Inc. to assist with its shareholder communications efforts. Cameron Associates is a leading investor relations and strategic advisory firm. Vicor Technologies is a development-stage biotechnology company focused on the commercialization of innovative non-invasive diagnostics for sudden cardiac death and trauma using its patented, proprietary PD2i algorithm.

Cameron will assist Vicor Technologies in broadening its financial market presence and establishing new relationships within the investment community. The firm has a wealth of experience representing fast growing emerging healthcare and technology companies.

"Vicor Technologies is making rapid progress in commercializing its innovative non-invasive diagnostics using its patented, proprietary PD2i algorithm," stated David H. Fater, Vicor President and CEO. "An important priority going forward is to build a stronger relationship with and to transmit a deeper understanding of our business to a variety of constituencies in the capital markets, including institutional shareholders and analysts," he continued. "We believe Cameron Associates, which has an excellent track record and a unique, compelling service model is an excellent fit for us. We look forward to benefiting from their insight into the marketplace and from their relationships within the capital markets," Mr. Fater concluded.

About Cameron Associates, Inc.

Cameron Associates, founded in 1976, is a New York-based, full-service investor relations firm that currently advises over 35 public companies.

About Vicor Technologies, Inc.

Vicor Technologies is a development-stage biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i.) The PD2i is a deterministic, non-linear measure that analyzes electrophysiological potentials to predict future pathological events with a high degree of accuracy in target populations. Vicor currently has three products employing the PD2i algorithm. The PD2i Analyzer, now in commercialization, measures heart rate variability. The PD2i VS (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA (Cardiac Analyzer), currently involved in multiple clinical trials, identifies patients at risk of suffering sudden cardiac death.